Clinical trials
Pulmonary Arterial Hypertension trials in Argentina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Terminated | 14 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Actelion | 7 |
| United Therapeutics | 5 |
| Merck Sharp & Dohme LLC | 4 |
| Bayer | 3 |
| Insmed Incorporated | 3 |
| Novartis Pharmaceuticals | 3 |
| Pfizer | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Aerovate Therapeutics | 2 |
| Biogen | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Arterial Hypertension | 41 |
| Hypertension, Pulmonary | 16 |
| Hypertension | 3 |
| Cardiovascular Diseases | 2 |
| Connective Tissue Diseases | 2 |
| Familial Primary Pulmonary Hypertension | 2 |
| Lung Diseases | 2 |
| Respiratory Tract Diseases | 2 |
| Vascular Diseases | 2 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.